Vaxart Past Earnings Performance
Past criteria checks 0/6
Vaxart's earnings have been declining at an average annual rate of -25.9%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 10.1% per year.
Key information
-25.9%
Earnings growth rate
5.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 10.1% |
Return on equity | -105.7% |
Net Margin | -431.6% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding
Nov 16There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump
Aug 20An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued
Jun 15Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
Nov 08Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely
Jun 30Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis
Sep 09Ray Stapleton joins Vaxart as CTO
Aug 31Vaxart shareholders approve proposal to increase number of shares
Aug 05Vaxart continues to lobby shareholders to vote to increase number of shares
Jul 29Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2
Jul 20Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success
Jul 07Vaxart: A Unique Vaccine Concern
Jun 14Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform
Feb 26Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow
Dec 09Vaxart: Differentiated Covid Oral Route Remains Viable
Nov 16Revenue & Expenses Breakdown
How Vaxart makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 17 | -72 | 22 | 0 |
30 Jun 24 | 14 | -76 | 23 | 0 |
31 Mar 24 | 9 | -82 | 23 | 0 |
31 Dec 23 | 7 | -82 | 23 | 0 |
30 Sep 23 | 4 | -89 | 24 | 0 |
30 Jun 23 | 2 | -101 | 26 | 0 |
31 Mar 23 | 1 | -108 | 29 | 0 |
31 Dec 22 | 0 | -108 | 29 | 0 |
30 Sep 22 | 0 | -105 | 29 | 0 |
30 Jun 22 | 0 | -93 | 27 | 0 |
31 Mar 22 | 0 | -80 | 23 | 0 |
31 Dec 21 | 1 | -70 | 22 | 0 |
30 Sep 21 | 1 | -64 | 21 | 0 |
30 Jun 21 | 1 | -54 | 20 | 0 |
31 Mar 21 | 2 | -47 | 19 | 0 |
31 Dec 20 | 4 | -32 | 15 | 0 |
30 Sep 20 | 8 | -25 | 11 | 0 |
30 Jun 20 | 8 | -22 | 9 | 0 |
31 Mar 20 | 7 | -19 | 6 | 0 |
31 Dec 19 | 10 | -19 | 6 | 0 |
30 Sep 19 | 8 | -17 | 6 | 0 |
30 Jun 19 | 8 | -18 | 6 | 0 |
31 Mar 19 | 8 | -22 | 7 | 0 |
31 Dec 18 | 4 | -18 | 7 | 0 |
30 Sep 18 | 3 | -15 | 6 | 0 |
30 Jun 18 | 4 | -12 | 5 | 0 |
31 Mar 18 | 5 | -7 | 3 | 0 |
31 Dec 17 | 6 | -12 | 3 | 0 |
30 Sep 17 | 9 | -16 | 3 | 0 |
31 Dec 16 | 8 | -19 | 3 | 0 |
31 Dec 15 | 0 | -22 | 3 | 0 |
Quality Earnings: VXRT is currently unprofitable.
Growing Profit Margin: VXRT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VXRT is unprofitable, and losses have increased over the past 5 years at a rate of 25.9% per year.
Accelerating Growth: Unable to compare VXRT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VXRT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: VXRT has a negative Return on Equity (-105.69%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 06:38 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vaxart, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Mayank Mamtani | B. Riley Securities, Inc. |
Charles Duncan | Cantor Fitzgerald & Co. |
Vernon Bernardino | H.C. Wainwright & Co. |